Want to see GB:OPTI full AI Analyst Report?
Top Page
OptiBiotix Health
(LSE:OPTI)
Select Model
Select Model
Rating:46Neutral
Price Target:
5.50 p
▼(-1.79% Downside)
Action:Reiterated
Date:07/17/26
The score is primarily held back by ongoing losses and persistent cash burn despite strong recent revenue growth and improved gross margins. A debt-light balance sheet helps, but technical signals are mixed with the price below key short-term averages. Valuation remains constrained by negative earnings and no provided dividend yield.
Positive Factors
B2B licensing model
OptiBiotix’s core B2B licensing and ingredient-supply model creates scalable, low-capex revenue channels. Licensing enables royalty and fee income tied to partner sales, leveraging third-party distribution and brand reach for sustainable revenue without heavy in-house retail investment.
Negative Factors
Persistent cash burn
Sustained negative operating cash flow requires ongoing external funding, increasing dilution or refinancing needs. Persistent cash burn constrains investment in commercialization and R&D, shortens runway absent partner-generated royalties, and represents a clear medium-term liquidity risk for the business model.
Read all positive and negative factors
Positive Factors
Negative Factors
B2B licensing model
OptiBiotix’s core B2B licensing and ingredient-supply model creates scalable, low-capex revenue channels. Licensing enables royalty and fee income tied to partner sales, leveraging third-party distribution and brand reach for sustainable revenue without heavy in-house retail investment.
Read all positive factors
OptiBiotix Health (OPTI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.84M
Dividend YieldN/A
Average Volume (3M)268.80K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth34.02%
EPS Growth-93.85%
CountryUK
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding103,300,300
10 Day Avg. Volume266,472
30 Day Avg. Volume268,800
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)5.86
P/FCF Ratio-3.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OptiBiotix Health Business Overview & Revenue Model
Company Description
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, a...
How the Company Makes Money
OptiBiotix primarily makes money by commercialising its microbiome-related intellectual property through business-to-business agreements rather than operating as a large direct-to-consumer brand. The main revenue streams are: (1) Licensing and com...
OptiBiotix Health Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17M | 870.00K | 644.00K | 457.00K | 2.21M |
| Gross Profit | 614.00K | 331.00K | 320.00K | 244.00K | 1.12M |
| EBITDA | -2.93M | -2.06M | -1.84M | 2.75M | 6.51M |
| Net Income | -3.89M | -1.80M | -2.04M | 2.59M | 6.26M |
Balance Sheet | |||||
| Total Assets | 6.89M | 9.04M | 9.40M | 11.55M | 20.14M |
| Cash, Cash Equivalents and Short-Term Investments | 1.04M | 739.00K | 635.00K | 1.05M | 2.01M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 819.36K |
| Total Liabilities | 610.00K | 647.00K | 532.00K | 643.00K | 1.97M |
| Stockholders Equity | 6.28M | 8.40M | 8.87M | 10.90M | 18.14M |
Cash Flow | |||||
| Free Cash Flow | -1.77M | -1.77M | -1.53M | -1.28M | -1.76M |
| Operating Cash Flow | -1.77M | -1.77M | -1.53M | -1.11M | -1.56M |
| Investing Cash Flow | 1.35M | 587.00K | 1.11M | -331.00K | -193.51K |
| Financing Cash Flow | 713.00K | 1.28M | 0.00 | 485.00K | 2.90M |
OptiBiotix Health Technical Analysis
Negative
5.60
Price Trends
5.99
Negative
5.73
Negative
6.31
Negative
Market Momentum
-0.08
Negative
37.65
Neutral
36.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OPTI, the sentiment is Negative. The current price of 5.6 is below the 20-day moving average (MA) of 5.71, below the 50-day MA of 5.99, and below the 200-day MA of 6.31, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 37.65 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OPTI.
OptiBiotix Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £25.59M | -52.78 | -5.25% | ― | 95.16% | 85.60% | |
50 Neutral | £4.19M | -1.77 | -37.30% | ― | ― | 85.56% | |
46 Neutral | £5.84M | -1.49 | -52.92% | ― | 34.02% | -93.85% | |
43 Neutral | £2.56M | -0.17 | -310.00% | ― | -87.82% | -746.51% | |
43 Neutral | £3.95M | -2.97 | -83.53% | ― | ― | 93.02% | |
40 Underperform | £6.80M | -9.41 | 104.99% | ― | ― | 69.64% |
* Healthcare Sector Average
GB:OPTI
OptiBiotix Health
5.65
-6.98
-55.25%
GB:TCF
Evgen Pharma
0.19
-0.03
-13.64%
GB:FUM
Futura Medical
0.44
-8.88
-95.29%
GB:NFX
Nuformix Plc
0.14
0.06
68.67%
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.50
-0.05
-3.23%
GB:SBTX
SkinBioTherapeutics
9.50
-5.50
-36.67%
OptiBiotix Health Corporate Events
Business Operations and StrategyProduct-Related Announcements
OptiBiotix to brief investors after SweetBiotix sampling success
Positive
Jun 26, 2026
OptiBiotix Health will host a live investor presentation and QA on 2 July 2026 via its Investor Hub, following successful SweetBiotix sampling on 24 June. Chief executive Stephen O’Hara will update investors on the commercial progress of fir...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix sets London investor event to showcase SweetBiotix and product pipeline
Positive
Jun 2, 2026
OptiBiotix Health will host an investor presentation and SweetBiotix sampling evening in central London on 24 June 2026, following strong interest after an earlier announcement. The event is designed to showcase commercial progress of its first-ge...
Business Operations and StrategyRegulatory Filings and Compliance
OptiBiotix Finance Director Increases Stake With Share Purchase
Positive
May 29, 2026
OptiBiotix Health plc reported that finance director David Blain has increased his stake in the company by purchasing 158,965 ordinary shares at 6.17 pence each on 28 May 2026. Following the transaction, Blain now holds 243,018 shares, representin...
Business Operations and StrategyFinancial Disclosures
OptiBiotix lifts revenues and margins as it pivots to profitability and tighter cost control
Positive
May 28, 2026
OptiBiotix Health reported strong trading for 2025, with revenue up 34% to £1.17m, gross profit rising 85% to £614k and margins improving to 53%, supported by growing international sales that now account for 73% of turnover, particularly...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix to Showcase Enhanced SweetBiotix Sugar Substitute at London Investor Event
Positive
May 14, 2026
OptiBiotix Health plans to showcase its SweetBiotix sugar-substitute fibres to shareholders at a sampling event in London in June 2026, following a reported manufacturing breakthrough that delivers higher yields, purer and better-tasting product, ...
Business Operations and StrategyPrivate Placements and Financing
OptiBiotix boosts cash runway with partial sale of SkinBioTherapeutics stake
Positive
May 1, 2026
OptiBiotix Health has sold 7.5 million shares in SkinBioTherapeutics, raising £675,000 in cash that will be applied to general working capital and is expected to extend the company’s funding runway into the first half of 2027. Following...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.